Last reviewed · How we verify

Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

NCT00346827 Phase 2/Phase 3 COMPLETED

To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.

Details

Lead sponsorBritannia Pharmaceuticals Ltd.
PhasePhase 2/Phase 3
StatusCOMPLETED
Enrolment36
Start date2006-07
Completion2007-08

Conditions

Interventions